GLP-1

Phase 2Biologic

RRigshospitalet, Denmark

GLP-1 is one of 498 biologic programs targeting Insulin resistance. It is currently in Phase 2.

Indications

Total Trials

Active Trials

497

Competitors

Pipeline

Status by Indication[3][1]

Indication

Insulin ResistanceActive, not recruiting

Endothelial DysfunctionActive, not recruiting

Binge EatingActive, not recruiting

Insulin SecretionActive, not recruiting

Angina PectorisActive, not recruiting

Type 2 Diabetes MellitusActive, not recruiting

Myocardial InfarctionActive, not recruiting

Weight LossActive, not recruiting

Gastrointestinal DiseaseActive, not recruiting

Congestive Heart FailureActive, not recruiting

Insulin ResistancePreclinical

Active, not recruiting

Endothelial DysfunctionPreclinical

Active, not recruiting

Binge EatingPreclinical

Active, not recruiting

Insulin SecretionPhase 1

Active, not recruiting

Angina PectorisPhase 1

Active, not recruiting

Type 2 Diabetes MellitusPhase 2

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Weight LossPhase 2

Active, not recruiting

Gastrointestinal DiseasePhase 1

Active, not recruiting

Congestive Heart FailurePreclinical

Active, not recruiting

Showing 10 of 19 indications

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

GLP-1

RRigshospitalet, Denmark

Phase 2

1 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

NOVOLIN R

Novo Nordisk

Preclinical

5 4

Cysteine Hydrochloride

Novartis

Preclinical

1 5

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 6

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 7

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 8

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

Forxiga

AstraZeneca

Preclinical

3 10

Sulfonylureas

Eli Lilly

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Cystic Fibrosis

NCT01851694

Q2 2027

N/ARecruiting

Infusion

NCT07398300

Q4 2027

N/ARecruiting

Function

NCT06194955

Q3 2028

Recruiting

Multiple Sclerosis

NCT07207148

Clinical

Trials by Indication[1]

GLP-13 trials

GLP-1 Medicines and Mental Health Changes

Completed·UUniversity of California, San Diego·N/A·NCT07368855·90 enrolled

Characterizing the Incretin Effect of Amino Acids and Defining GLP-1 Role on Skeletal Muscle

Completed·UUniversity of Nottingham·N/A·NCT02370745·40 enrolled

Intact Vagal Innervation and Glucagon-like Peptide-1 (GLP-1) Effects

Unknown status·UUniversity Hospital, Gentofte, Copenhagen·N/A·NCT01176890·30 enrolled

Heart Failure2 trials

Effect of 48 Hours of Treatment With the Natural Peptide-Hormone GLP-1 in Patients With Chronic Heart Failure

Completed·—·N/A·NCT00264199·20 enrolled

Effects of GLP-1 on Chronic Heart Failure

Unknown status·SShi Yang·N/A·NCT02650596·68 enrolled

Hyperglycemia1 trial

Hyperglycemia and the Extra-pancreatic Effect of Incretins

Completed·RRigshospitalet, Denmark·N/A·NCT01749163·20 enrolled

Cystic Fibrosis1 trial

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

Recruiting·UUniversity of Pennsylvania·N/A·NCT01851694·45 enrolled

Type 2 Diabetes1 trial

Comparative Cardiovascular Effectiveness of GLP-1 RAs vs. Insulin in Early-Onset Type 2 Diabetes

Completed·KKarolinska Institutet··NCT06913881·92,100 enrolled

25 more indications

Diabetes Mellitus1 trial

Umbilical Cord Mesenchymal Stem Cells and Liraglutide in Diabetes Mellitus

Unknown status·DDiabetes Care Center of Nanjing Military Command·Phase 1/2·NCT01954147·100 enrolled

Binge Eating1 trial

Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity

Recruiting·HHaukeland University Hospital··NCT07042672·80 enrolled

Cognitive Function1 trial

To Determine the Effect of GLP1 on Cognitive Function, Brain Glucose Metabolism and Neuroplasticity.

Completed·UUniversity of Pisa·N/A·NCT03414333·14 enrolled

Intravenous1 trial

Effects of Intravenous Infusions of Gut Hormones on Appetite and Metabolism.

Completed·UUniversity of Copenhagen·N/A·NCT00940134·24 enrolled

Humans1 trial

GLP-1 Inhibits Prandial Antro-duodeno-jejunal Motility in Humans

Completed·UUppsala University·Phase 1·NCT02731664·12 enrolled

Myocardial Infarction1 trial

GLP-1 on Non-ST-Segment Elevation Myocardial Infarction

Unknown status·—·N/A·NCT02577848·90 enrolled

Insulin resistance1 trial

Mechanisms of Insulin Resistance in Critical Illness: Role of Systemic Inflammation and GLP-1

Completed·RRigshospitalet, Denmark·N/A·NCT01347801·40 enrolled

Type 1 Diabetes1 trial

Effect of GLP-1 on Microvascular Insulin Responses in Type 1 Diabetes

Withdrawn·UUniversity of Virginia·Phase 1·NCT04133922

Weight loss1 trial

The Effect of Surgically Induced Weight Loss on Endocrine Function, Cardiovascular Function and Body Composition

Terminated·JJohns Hopkins University·Phase 2·NCT00686972·51 enrolled

Infusion1 trial

Insulin-Mediated Glucose Uptake and Organ Perfusion Assessed by Total-Body PET During GIP and GLP-1 Infusion

Recruiting·RRigshospitalet, Denmark·N/A·NCT07398300·36 enrolled

Quality of Life1 trial

Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures

Enrolling by invitation·AAgelessRx·Phase 1·NCT07092605·150 enrolled

Obesity1 trial

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

Completed·TTurku University Hospital·Phase 1·NCT01880827·36 enrolled

Insulin Secretion1 trial

Incretin Regulation of Insulin Secretion in Monogenic Diabetes

Completed·UUniversity of Chicago·Phase 1·NCT01795144·10 enrolled

Function1 trial

The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function

Recruiting·UUniversity of Copenhagen·N/A·NCT06194955·60 enrolled

Multiple Sclerosis1 trial

People With Multiple Sclerosis Treated With Ocrelizumab and GLP-1 Agonists

Recruiting·NNorthwestern University··NCT07207148·100 enrolled

Metabolism1 trial

Effect of GLP-1 on Postprandial Lipid Metabolism

Unknown status·DDavid Dalessio·N/A·NCT01760772·42 enrolled

Intraoperative1 trial

GLP 1 for Intraoperative Glycemic Control

Completed·UUniversity of Pennsylvania·Phase 1·NCT00882492·80 enrolled

Percutaneous Coronary Intervention1 trial

GLP-1 Loading During Elective Percutaneous Coronary Intervention

Unknown status·PPapworth Hospital NHS Foundation Trust·Phase 2·NCT02127996·193 enrolled

Type 2 Diabetic Patients1 trial

Efficacy of GLP-1 Infusion in Comparison to an Insulin Infusion Protocol to Reach Normoglycemia Type 2 Diabetic Patients

Completed·MMedical University of Graz·Phase 4·NCT00859079·8 enrolled

Microvascular Function1 trial

The Microvascular Function of GLP-1 and Its Analogues

Completed·KKatarina Kos·N/A·NCT01677104·63 enrolled

Endothelial Dysfunction1 trial

Glucagon-like Peptide 1 (GLP-1) and Endothelial Dysfunction in Metabolic Syndrome

Completed·UUniversity of Rome Tor Vergata·N/A·NCT00856700·20 enrolled

Diabetes1 trial

Incretin Action in Physiology and Diabetes

Completed·—·Phase 1·NCT02550548·39 enrolled

Homeostasis1 trial

Effects of Oral GLP-1 on Glucose Homeostasis and Appetite Profile in Healthy Male Subjects

Completed·UUniversity Hospital, Basel, Switzerland·Phase 1/2·NCT00822003·16 enrolled

Bariatric Surgery1 trial

Pretreatment of Patients Expecting Bariatric Surgery With the GLP-1 Analogon Liraglutid

Terminated·UUniversitätsklinikum Hamburg-Eppendorf·Phase 3·NCT02417103·2 enrolled

Unspecified2 trials

GLP1R Polymorphisms and Response to GLP1

Completed·MMayo Clinic·N/A·NCT00588380·88 enrolled

Characterization of Beta Cell Failure

Withdrawn·UUniversity Hospital Tuebingen·N/A·NCT00869102

Sources

References

[1]
ClinicalTrials.gov — 34 trial records for GLP-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-1 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-1. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rigshospitalet, Denmark company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: RRigshospitalet, Denmark

GLP-1

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q3 2028

Trials by Indication[1]

GLP-13 trials

Heart Failure2 trials

Hyperglycemia1 trial

Cystic Fibrosis1 trial

Type 2 Diabetes1 trial

Diabetes Mellitus1 trial

Binge Eating1 trial

Cognitive Function1 trial

Intravenous1 trial

Humans1 trial

Myocardial Infarction1 trial

Insulin resistance1 trial

Type 1 Diabetes1 trial

Weight loss1 trial

Infusion1 trial

Quality of Life1 trial

Obesity1 trial

Insulin Secretion1 trial

Function1 trial

Multiple Sclerosis1 trial

Metabolism1 trial

Intraoperative1 trial

Percutaneous Coronary Intervention1 trial

Type 2 Diabetic Patients1 trial

Microvascular Function1 trial

Endothelial Dysfunction1 trial

Diabetes1 trial

Homeostasis1 trial

Bariatric Surgery1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News